



Belite Bio Announces Agreement to Assign Exclusive License Agreement with Columbia University to Belite Swiss

November 24, 2025

SAN DIEGO, November 24, 2025 - [Belite Bio, Inc.](#) (NASDAQ: BLTE, the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its wholly owned subsidiary, Belite Bio (HK) Limited (“Belite HK”), has entered into a Contribution Agreement with Belite Bio (Swiss) AG (“Belite Swiss”), wholly owned by Belite HK, for assignment of Belite Bio’s rights, title, interests and obligations under the exclusive license agreement with Trustees of Columbia University in the City of New York (“Columbia University”), as part of its capital contribution to Belite Swiss.

The foregoing assignment from Belite HK to Belite Swiss was aimed to optimize the tax structure of the Company in the event that the Company enters into any potential sub-licensing or collaboration in the future. This assignment will not affect Belite Bio’s business and operations.

Belite Bio has obtained the required consent from Columbia University for the foregoing assignment.

About Belite Bio

Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need, such as STGD1 and GA in advanced dry AMD, in addition to specific metabolic diseases. Belite’s lead candidate, Tinklarebant, an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on [X](#), [Instagram](#), [LinkedIn](#), and [Facebook](#) or visit us at [www.belitebio.com](#).

Important Cautions Regarding Forward Looking Statements

This press release contains forward-looking statements about future expectations and plans, as well as other statements regarding matters that are not historical facts. These statements include but are not limited to statements regarding the potential implications of clinical data for patients, and Belite Bio’s advancement of, and anticipated preclinical activities, clinical development, regulatory milestones, and commercialization of its product candidates, the ability of Tinklarebant to treat Stargardt disease and geographic atrophy, and any other statements containing the words “expect”, “hope” and similar expressions. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to Belite Bio’s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; the content and timing of any potential sub-licensing or collaboration in the future, as well as those risks more fully discussed in the “Risk Factors” section in Belite Bio’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Belite Bio, and Belite Bio undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Media and Investor Relations Contact:

Jennifer Wu
ir@belitebio.com

Julie Fallon
belite@argotpartners.com